Veteran drug hunter adds discovery expertise to technology-enabled biopharma company SAN FRANCISCO, Calif. — September 14, 2022 — Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced the appointment of Gavin Hirst, Ph.D., as Chief Scientific Officer. Dr. Hirst brings more than 30 years of expertise in drug discovery […]
CSO, CFO, and GC added as technology-enabled pharma company bolsters growing management team and SAB SAN FRANCISCO, Calif. — January 25, 2022 — Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, announced today the appointment of David Thomson, Ph.D. as Chief Scientific Officer. Additional management team appointments include Jonathan Barr […]
Atomwise recognized for achievements in AI-driven drug discovery and creation of the AtomNet® platform, which has tackled — and succeeded in — finding small molecule hits for more undruggable targets than any other platform NEW YORK, August 13, 2020 — CB Insights today named Atomwise to its second annual Digital Health 150 ranking, which showcases […]
Angus Liu of FierceBiotech reports on new research on Miro1 and implications for Parkinson’s disease.